INDEPENDENT VERDICT
Amplica Bio, Inc. is a newly formed Delaware biotechnology company whose first SEC Form D provides very little capital but unusually useful identity evidence. The September 11 filing reports an indefinite offering, $30,000 sold to one investor following a September 2 first sale, and securities consisting of both Equity and a Simple Agreement for Future Equity. Amplica relies on Rule 506(b), is not a pooled investment fund, reports no commissions, finder fees or related-person use of proceeds, and declines to disclose revenue. Kush Daksheish Mehta is identified as an executive officer and director and signs as Chief Business Officer, while Kaustav Aras Gopinathan is listed as an executive officer. The strongest immediate conclusion is therefore that Amplica is a genuine but extremely early-stage operating biotech whose product, valuation, investor and ultimate fundraising target remain non-public.
THE FIRST DILIGENCE PROBLEM IS IDENTITY: AMPLICA IS NOT AMPLIFICA
Amplica presents an unusually important entity-resolution problem because another established biotechnology company is named Amplifica Holdings Group, Inc. and operates at amplificabio.com. Amplifica is a San Diego clinical-stage company developing injectable treatments for androgenetic alopecia; in August 2026 it announced an oversubscribed $26 million Series B led by Tasso Partners with participation from Eli Lilly and principals of Scopia Capital Management. Amplica Bio's SEC filing, by contrast, identifies a company incorporated in 2026, headquartered for filing purposes in Wilmington, Delaware, with $30,000 sold and executives Kush Mehta and Kaustav Gopinathan. At least one automated Form D service has already attached amplificabio.com to Amplica Bio, illustrating exactly why legal-name, CIK, personnel and address verification are necessary before using a same-sounding website. FilingDossier does not treat amplificabio.com, Amplifica's clinical candidates or its $26 million Series B as belonging to Amplica Bio.
THE TEAM BACKGROUND POINTS TOWARD A VERY DIFFERENT KIND OF BIOTECH
The most informative public evidence comes from the two SEC-listed executives. Kaustav Gopinathan is a Harvard-MIT physician-scientist who completed an MIT undergraduate degree, a Harvard PhD in Biophysics and a Harvard Medical School MD, with research at Massachusetts General Hospital's Center for Engineering in Medicine and Surgery. His doctoral work produced a Nature paper describing a "microfluidic transistor," a component designed to control the flow of liquids and suspended particles analogously to how electronic transistors control current. The research demonstrated that classical electronic circuit concepts could be translated into microfluidic circuits capable of automatically manipulating fluids and particles, with potential applications in high-throughput biological processing, cell handling, molecular assays and lab-on-chip systems. Kush Mehta brings a complementary profile: University of Pennsylvania bioengineering training, earlier research in mesenchymal stem-cell mechanobiology, later healthcare product and strategy experience, and a current public professional profile describing work at a stealth biotechnology startup. That combination of deep microfluidic science and healthcare commercialization is far more specific than the generic "Biotechnology" box selected in Form D.
THE MICROFLUIDIC-TRANSISTOR CONNECTION IS COMPELLING — BUT THE IP DOES NOT YET BELONG TO AMPLICA ON THE PUBLIC RECORD
Gopinathan's scientific background creates a plausible hypothesis that Amplica could be developing tools that automate biological or chemical processing, but there is an important evidence boundary. Public patent records for "Fluidic transistors and uses thereof" identify Gopinathan and Mehmet Toner among the inventors and list General Hospital Corporation as assignee. The Nature work likewise originated at Massachusetts General Hospital rather than Amplica Bio. More recent academic work has demonstrated microfluidic-transistor concepts in applications such as autonomous cryoprotectant loading of oocytes, showing that the platform can move beyond a single proof-of-concept circuit into automated biological manipulation. None of the reviewed public records, however, shows an exclusive license, assignment or sponsored-research agreement transferring this IP to Amplica. Investors should therefore treat the founders' scientific history as highly relevant team evidence but should not assume that Amplica owns, licenses or commercializes the MGH technology until a license, patent assignment or company statement establishes that connection.
THE $30K FORM D LOOKS MORE LIKE CAPITALIZATION FORMATION THAN A FULL BIOTECH ROUND
The financing itself reinforces how early Amplica appears to be. The company selected an indefinite total offering rather than a fixed fundraising target, reported only $30,000 sold to one investor and simultaneously selected Equity and SAFE securities. That combination can occur when a newly incorporated company begins establishing its capitalization before a larger institutional seed round, although the Form D does not disclose whether the $30,000 investor is a founder, angel, strategic participant or unrelated third party. It also does not reveal the SAFE valuation cap, discount, most-favored-nation rights, share class, pre-money valuation, IP contribution or the percentage of Amplica purchased by the investor. The Delaware filing address appears to function as an administrative address rather than providing evidence of a laboratory footprint, and no independently verified corporate website currently discloses Amplica's pipeline, assays, employees, laboratory, collaborations or commercial product. For a biotechnology company this early, the highest-value diligence documents are therefore the capitalization table, SAFE agreement, certificate of incorporation, IP-assignment agreements, founder employment agreements, laboratory location, university/MGH license arrangements and a technical description of the first product rather than speculation based on the company name.
FINAL ASSESSMENT
Amplica Bio's first Form D is small financially but unusually valuable from a verification perspective. SEC EDGAR establishes a new 2026 Delaware biotechnology corporation, $30,000 sold to one investor, an indefinite Rule 506(b) offering, Equity plus SAFE securities, and a leadership team consisting of Kush Mehta and Kaustav Gopinathan. Independent academic evidence gives that team credible biotechnology depth, especially Gopinathan's work on programmable microfluidic control of cells, particles and liquids, while Mehta combines bioengineering research with healthcare commercialization experience. What the evidence does not yet reveal is what Amplica is actually building, which intellectual property it owns and whether the MGH microfluidic-transistor platform forms part of its business.
The strongest independent finding is therefore twofold. First, Amplica must be kept completely separate from Amplifica Holdings Group, the unrelated hair-growth biotech whose near-identical name has already caused automated website matching errors. Second, Amplica's founder profile suggests a potentially distinctive bioengineering platform, but the most obvious underlying scientific IP remains publicly assigned outside the company. That creates a clear future verification path: a patent assignment, MGH license, product launch, scientific publication, hiring page or larger Form D could reveal whether Amplica is commercializing programmable microfluidics or pursuing a different biotechnology thesis entirely. Until that evidence appears, FilingDossier can verify the company, financing and team — but not the product or IP ownership.
Form D is an exempt-offering notice. It is not SEC approval of Amplica Bio, its SAFE securities, any microfluidics technology, its executives or any future biotechnology product.
SEC SNAPSHOT
ISSUER: Amplica Bio, Inc. | CIK: 0002154543 | SEC FILE NO.: 021-597157 | FILM NO.: 261373155 | ACCESSION NO.: 0002154543-26-000001 | FILED / EFFECTIVE: September 11, 2026
ENTITY: Delaware Corporation | INCORPORATED: 2026 | PRINCIPAL SEC ADDRESS: 2810 N Church St, Suite 90465, Wilmington, DE 19802 | PHONE: 646-907-9591
INDUSTRY: Biotechnology | EXEMPTION: Regulation D Rule 506(b) | POOLED INVESTMENT FUND: No | INVESTMENT COMPANY ACT EXCLUSION: None claimed
SECURITIES: Equity | Simple Agreement for Future Equity (SAFE) | BUSINESS COMBINATION: No | FIRST SALE: September 2, 2026
TOTAL OFFERING: Indefinite | AMOUNT SOLD: $30,000 | REMAINING: Indefinite | INVESTORS: 1 | MINIMUM INVESTMENT FIELD: $0
REVENUE RANGE: Declined to disclose | SALES COMMISSIONS: $0 | FINDER FEES: $0 | ITEM 16 RELATED-PERSON PAYMENTS: $0
RELATED PERSONS: Kush Daksheish Mehta — Executive Officer / Director | Kaustav Aras Gopinathan — Executive Officer
FORM D SIGNATORY: Kush Mehta | TITLE: Chief Business Officer
KAUSTAV GOPINATHAN BACKGROUND: MIT undergraduate | Harvard PhD in Biophysics | Harvard Medical School MD | Massachusetts General Hospital research | doctoral work focused on microfluidic transistors for automated control of liquids and particles.
KUSH MEHTA BACKGROUND: University of Pennsylvania BSE/MSE Bioengineering | prior mesenchymal stem-cell mechanobiology research | later healthcare product / commercialization experience | current public profile references a stealth biotechnology startup.
RELEVANT MICROFLUIDICS RESEARCH: Gopinathan and collaborators published a Nature study demonstrating a microfluidic transistor architecture capable of translating electronic-style circuit logic into automated fluid and particle control.
IP OWNERSHIP LIMITATION: Public patent records for "Fluidic transistors and uses thereof" identify General Hospital Corporation as assignee. No reviewed public evidence establishes assignment or licensing of those patents to Amplica Bio.
OFFICIAL WEBSITE: Not independently confirmed.
IMPORTANT NAME WARNING: Amplica Bio, Inc. is not verified as the same entity as Amplifica Holdings Group, Inc. / amplificabio.com. Amplifica is a separate San Diego clinical-stage hair-growth biotechnology company that announced a $26M Series B in August 2026. Its financing, pipeline and investors should not be attributed to Amplica.
THIRD-PARTY DATA QUALITY NOTE: At least one Form D aggregation service currently associates Amplica Bio with amplificabio.com despite the legal entities, leadership, financing and operating histories being different. This illustrates why automated website matches should be checked against SEC CIK and officer data before publication.
CORE INDEPENDENT FINDING: Amplica Bio is currently more traceable through its founders than through its product. The SEC filing verifies a $30K first financing and a team combining biotechnology commercialization with Harvard-MIT/MGH microfluidics expertise, but the obvious academic IP remains publicly assigned to General Hospital Corporation and no verified company materials yet reveal Amplica's actual product. The central diligence question is therefore whether Amplica has licensed or developed new IP around programmable biological processing — and not whether it should be confused with the unrelated Amplifica hair-loss company.
Form D is an exempt-offering notice and is not an SEC-issued certificate, approval or endorsement.